



MEDISAFE



RAAJ MEDISAFE INDIA LIMITED

February 14, 2022

To,
BSE Ltd
Phiroze Jeejeebhoy Towers,
Dalal Street
MUMBAI-400001

SCRIP CODE: 524502

Dear Sir,

SUB. UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED DECEMBER 31, 2021.

Pursuant to clause 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 we enclose herewith-

- a. Unaudited Quarterly Financial Results of the Company for the quarter ended on December 31, 2021.
- b. Limited Review Report for the Quarter ended December 31, 2021 issued by Statutory Auditors of the company.

The above Statements/reports have been reviewed by audit committee and taken on record by the Board of Directors of the Company in its meeting held on February 14, 2021.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR RAAJ MEDISAFE INDIA LIMITED


ARPIT BANGUR
CHAIRMAN
DIN: 02600716



Enclose: As stated

Regd. Office : 106, Industrial Area, Sector III, Pithampur - 454 774, Dist. Dhar (M.P.) INDIA

Corporate Office : 224, Apollo Tower, 2 M.G. Road, Indore - 452 001 (M.P.) INDIA

Phone : 0731 4285155, **Fax :** +91 731 4285155

Email : raajmedisafe@gmail.com, **Website :** www.medisafeindia.com

CIN : L33112MP1985PLC003039, **GSTIN.** 23AABCM1901C1ZD

RAAJ MEDISAFE INDIA LIMITED
CIN - L33112MP1985PLC003039
Reg. Off. : 106, Sector III, Industrial Area, Pithampur, Dist - Dhar (M.P.)
STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31st DECEMBER 2021

		Statement of Standalone Results					
PARTICULARS		Quarter Ended			Nine Month ended		Year Ended
		31.12.21	30.09.21	31.12.20	31.12.21	31.12.20	31.03.21
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1		2	3	4	5	6	7
1	REVENUE FROM OPERATIONS						
	(a) Income from Operations (Sales of Products)	898.65	924.25	860.17	2,702.30	2,342.36	3,180.50
	(b) Other Operating Income	-	-	-	-	-	-
2	OTHER INCOME	0.36	0.69	0.17	8.96	1.45	2.04
3	Total Income (1+2)	899.01	924.94	860.34	2,711.26	2,343.81	3,182.54
4	EXPENSES						
	(a) Cost of Material Consumed	630.65	591.89	583.11	1,773.21	1,604.75	2,191.73
	(b) Purchases of Stock in Trade	-	-	-	-	-	-
	(c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	(23.14)	5.57	(6.08)	(12.02)	4.97	(9.44)
	(d) Employee benefits expense	67.00	81.36	77.48	224.24	173.83	244.25
	(e) Finance Cost	16.27	16.95	22.83	47.43	63.73	74.44
	(f) Depreciation and amortisation expense	18.81	16.74	16.53	51.81	50.91	71.10
	(g) Other expenses	77.20	74.81	101.84	264.24	246.25	347.36
	Manufacturing, Office and Admin. Expenses						
	Total Expenses	786.78	787.33	795.72	2,348.92	2,144.44	2,919.44
5	Profit/(Loss) before exceptional items and tax (3-4)	112.23	137.62	64.62	362.34	199.39	263.11
6	Exceptional Items	(0.09)	(0.49)	(0.49)	(1.13)	(0.69)	(1.23)
7	Profit/(Loss) from ordinary activities before tax (5-6)	112.14	137.12	64.13	361.21	198.70	261.87
8	Tax Expenses						
	(1) Current Tax	-	-	1.14	-	3.56	4.68
	(2) Deferred Tax	-	-	6.53	-	20.50	27.25
9	Net Profit/(Loss) for the period (7-8)	112.14	137.12	56.46	361.21	174.64	229.94
10	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	(2.14)	(3.00)	(2.13)	(3.90)
	(ii) tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
11	Total Comprehensive Income for the period (9+10)	112.14	137.12	54.32	358.21	172.51	226.04



Signature

12	Paid-up equity share capital (Face Value Rs. 10 Per Share)	1,090.20	1,090.20	1,090.20	1,090.20	1,090.20	1,090.20
13	Reserves excluding Revaluation Reserves	(983.00)	(983.00)	(1,209.04)	(983.00)	(1,209.04)	(983.00)
14	Earnings per share (of 10/- each) (not annualised) Before CI:						
	(a) Basic	1.03	1.25	1.99	3.28	1.58	2.07
	(b) Diluted	1.03	1.25	1.99	3.28	1.58	2.07
	See accompanying note to the financial results						

Notes:-

1	The Unaudited Standalone Financial Results were reviewed by the Audit Committee and approved at the meeting of Board of Directors of company held on 14th February 2022
2	Previous year's figures have been regrouped or re-arranged wherever necessary.
3	This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognized accounting practises and policies to the extent applicable
4	As per Ind AS 33, Earning Per Share, "Ordinary shares issued as part of the consideration transferred in a business combination are included in the weighted average number of shares from the appointed date of merger. This is because the Raaj Medisafe India Limited (Transferee Company) incorporates into its statement of profit and loss the Trasferor's company (Padma Polytex India Private Limited) profits and losses from that date." As per approved scheme of amalgamation is 01/04/2020. Further, As per Ind As 33, the retrospective effect of change or adjustment in number of ordinary shares be adjusted for all periods presented, the effect of change in number of ordinary shares is given also in Basic Earnings per Share and Diluted Earnings per Share.
5	The segment reporting is not applicable for the quarter ended Dec 31, 2021.
6	Nine Months Figures for 31/12/2020 are consolidated with merged with transfree company for comparison
7	Reserve excluding Revaluation reserve will be updated at the year end.

Place :- Ujjain
Dated :- 14/02/2022

For & On behalf of Board of Directors
For Raaj Medisafe India Limited


Arpit Bangur
Chairman
(DIN-02600716)



V.K. LADHA & ASSOCIATES

CHARTERED ACCOUNTANTS

36 DRAWID MARG, KSHIR SAGAR COLONY, UJJAIN

PH.(0734)2550498-99, Telefax: 0734-4040498 Mobile 98270-81499, 83199-18484

E-mail id: ladha@vkladha.com , vkladha99@hotmail.com

website: www.vkladha.com



Report on Review of Interim Financial Information

To,
Board of Directors of
Raaj Medisafe India Limited
Pithampur, Dist. Dhar - 454774

We have reviewed the accompanying statement of Standalone unaudited Financial Results of the Raaj Medisafe India Limited (CIN: L33112MP1985PLC003039) for the period ended 31.12.2021 being submitted by the company pursuant to the requirement of regulation 33 of the SEBI (Listing Objection and Disclosure Requirements) regulation 2015. This statement is the responsibility of the company's management and has been approved by the Board of Directors in charge. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Engagements to review Financial Statements" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, as supplemented by Notes forming part of accounts, nothing has come to our attention that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Ujjain

Date : 14/02/2022

UDIN: 22071501ACBOPD9044

For V.K. Ladha & Associates
Chartered Accountants
Firm Registration No. 002301C



CA V. K. Ladha
(Partner)
Membership No.: 071501